Menu
Recruiting NCT06319911

AETOS Shoulder System

— Observational Shoulder Osteoarthritis Shoulder Arthritis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: AETOS.
Who it may be relevant to
Registry conditions: Shoulder Osteoarthritis, Shoulder Arthritis. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

AETOS Shoulder System Post Market Clinical Investigation

Overview

The goal of this study is to confirm the safety and performance of the AETOS Shoulder System for USA adoption. This is a prospective, open, adaptive, non-comparative, multi-centre investigation enrolling a maximum of 220 subjects in 2 cohorts (anatomic and reverse) at up to 15 sites. No intra-study comparator group will be included, and there will be no randomization

Detailed description

This study will confirm the safety and performance of the AETOS Shoulder System in anatomic and reverse TSA. Revisions will not be enrolled into this study.

The AETOS Shoulder System is manufactured by Smith \& Nephew, Inc., 1450 Brooks Road Memphis, Tennessee 38116 USA, and has been 510k Cleared as of 07Jun2023; therefore, it is considered a post-market product and will be procured through normal commercial channels in the USA. The humeral stem is designed to be used for both Total Shoulder Arthroplasty (TSA) and reverse shoulder arthroplasty procedures. The humeral stems are designed with fins and a porous plasma coating to provide fixation within the proximal humeral metaphysis.

Interventions

  • Device AETOS
    The AETOS Shoulder System will be implanted into the right or left shoulder in the anatomic or reverse configuration

Primary outcome measures

  • Implant Survivorship [Time frame: 2 years]
Secondary outcome measures (12)
  • Implant Survivorship at 6 months, 1 year, 3.5 years and 5 years [Time frame: 6 months, 1 year, 3.5 years, and 5 years]
  • Radiographic Assessment - Glenoid Migration/Subsidence [Time frame: Day 0, 1 year, 2 years, and 5 years]
  • Radiographic Assessment - Glenoid Radiolucency [Time frame: Day 0, 1 year, 2 years, and 5 years]
  • Radiographic Assessment - Humeral Radiolucency [Time frame: Day 0, 1 year, 2 years, and 5 years]
  • Radiographic Assessment - Humeral Migration/Subsidence [Time frame: Day 0, 1 year, 2 years, and 5 years]
  • Radiographic Assessment - Humeral Head Centeredness [Time frame: Day 0, 1 year, 2 years, and 5 years]
  • Radiographic Assessment - Bone Remodeling [Time frame: Day 0, 1 year, 2 years, and 5 years]
  • Radiographic Assessment - Glenohumeral Subluxation [Time frame: Day 0, 1 year, 2 years, and 5 years]
  • Radiographic Assessment - Device Condition: Anatomic [Time frame: Day 0, 1 year, 2 years, and 5 years]
  • Radiographic Assessment - Device Condition: Reverse [Time frame: Day 0, 1 year, 2 years, and 5 years]
  • American Shoulder and Elbow Score (ASES) [Time frame: 6 months, 1 year, 2 years, and 5 years]
  • Constant Murley Score [Time frame: 6 months, 1 year, 2 years, and 5 years]

Eligibility criteria

Inclusion criteria

Patients must meet all the following criteria to be included in the study:

  • Patient is at least 18 years of age at the time of consent and skeletally mature.
  • Patient is undergoing a primary elective anatomic or reverse shoulder replacement surgery for one of the following indications:
  • Rheumatoid arthritis, and/or
  • Traumatic arthritis (Post Traumatic arthritis), and/or
  • Non-inflammatory degenerative joint disease, and/or
  • Correction of functional deformity.
  • Patient is willing and able to accommodate all study-related procedures and visits detailed in the protocol \& cooperate in the standard of care post-operative therapy.
  • Patient is geographically stable and willing to return to the study site for all follow-up visits.
  • Patient has been adequately informed of risks and requirements of the study and is willing and able to provide informed consent for participation.

\-

Exclusion criteria

Patients who meet any of the following criteria will not qualify for participation in the trial:

  • Patient has a contraindication to AETOS.
  • Patient is undergoing a revision shoulder replacement surgery including total or partial arthroplasty.
  • Patient is indicated for a Hemiarthroplasty.
  • Patient has traumatic injury or a fracture.
  • Patient has uncontrolled diabetes with a hemoglobin A1C of 7.5 or greater.
  • Patient has comorbidities/conditions that preclude proper healing/fixation of the implant.
  • Patient has poor quality or insufficient bone stock to support the implant.
  • Patient has poor bone quality where there could be considerable migration of the implant and/or a chance of fracture.
  • Patient has rapid joint destruction, marked bone loss or bone resorption (e.g., severe osteoporosis).
  • Patient has osteomalacia.
  • Patient has muscular, neurologic, or vascular deficiencies that may compromise the outcome of the shoulder replacement surgery.
  • Patient has a known sensitivity, allergic reaction, and/or known allergies to one or more of the implanted materials.
  • Patient has a distant foci of infection which may spread to the implant site, active local or systemic infection, sepsis, or osteomyelitis.
  • Patient has an elevation of sedimentation rate, elevation of WBC count, or marked shift in WBC differential count unexplained by other disease.
  • If reverse shoulder arthroplasty, patient has a non-functional deltoid or external rotator muscles.
  • If reverse shoulder arthroplasty, patient has a significant injury to the upper brachial plexus.
  • If reverse shoulder arthroplasty, patient has paralysis of the axillary nerve.
  • Patient is uncooperative, has a neurologic disorder and is not capable of following directions, or is a vulnerable subject per ISO 14155 (i.e., individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response).
  • Patient is pregnant or plans to become pregnant during the follow-up period.
  • Patient has a Body Mass Index (BMI) of >35kg/m2 or a BMI that may compromise the outcome of the shoulder replacement surgery.
  • Patient has anticipated activities which would impose high stresses on the implant and its fixation or has a high likelihood of a fall.
  • Patient is a known smoker, vaper, alcohol abuser, or drug abuser within 180 days of consent.
  • Patient has participated previously in this clinical trial and was withdrawn.
  • Patient is participating in another device or drug trial or observational competitive study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 5 centers
  • California Pacific Orthopedics — San Francisco
  • Western Orthopaedics — Denver
  • Hughston Foundation — Columbus
  • Center for Orthopedics and Neurosurgical Care — Bend
  • Rothman Institute — Philadelphia

Identifiers

NCT: NCT06319911 · AETOS 2022.04

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗